Puma Biotechnology
Puma Biotechnology is a biopharmaceutical company dedicated to the acquisition, development, and commercialization of novel therapeutics for the treatment of cancer.
Home About Us Product Pipeline News Investors Contacts Careers

News

Recent Press Releases Archives

Recent Press Releases

2014 News Releases

Dec. 12, 2014 - Puma Biotechnology Announces Positive Interim PB272 (Neratinib) Phase II Data at 2014 CTRC-AACR San Antonio Breast Cancer Symposium

Interim Phase II Results Demonstrate Efficacy of PB272 in Combination with Temsirolimus in HER2+ Metastatic Breast Cancer
Read

Dec. 2, 2014 - Puma Biotechnology Updates Timeline for Filing New Drug Application
-NDA Filing Currently Anticipated for Q1 2016
Read

Nov. 13, 2014 - Puma Biotechnology Announces Positive Top Line Results from PB272 Phase II Trial in HER2 Positive Metastatic Breast Cancer (NEfERTT Trial)
Read

Nov. 12, 2014 - Puma Biotechnology to Present at Stifel 2014 Healthcare Conference
Read

Nov. 10, 2014 - Puma Biotechnology Reports Third Quarter 2014 Financial Results
Read

Sept. 29, 2014 - Puma Biotechnology Announces Positive Initial Results from PB272 Phase II Trial in HER2 Mutated Non-Small Cell Lung Cancer
Read

Sept. 3, 2014 - Puma Biotechnology Announces Late-Breaking Oral Presentation on Neratinib in NSCLC with HER2 Mutations at ESMO 2014
Read

Aug. 11, 2014 - Puma Biotechnology Reports Second Quarter 2014 Financial Results
Read

July 22, 2014 - Puma Biotechnology Announces Positive Top Line Results from Phase III PB272 Trial in Adjuvant Breast Cancer (ExteNET Trial)
Read

July 22, 2014 - Puma Biotechnology Announces Amendment to Neratinib Licensing Agreement with Pfizer
Read

June 5, 2014 - Puma Biotechnology to Present at the Goldman Sachs 35th Annual Global Healthcare Conference
Read

June 1, 2014 - Puma Biotechnology Announces Presentation of Positive PB272 Phase II Data at the 2014 ASCO Annual Meeting
Read

May 29, 2014 - Puma Biotechnology to Present at Jefferies 2014 Global Healthcare Conference
Read

May 15, 2014 - Puma Biotechnology to Present at UBS Global Healthcare Conference
Read

May 14, 2014 - Puma Biotechnology Expands Cohort in Phase II Trial of PB272 (Neratinib) in HER2 Mutation-Positive Solid Tumor Patients
Read

May 12, 2014 - Puma Biotechnology Reports First Quarter 2014 Financial Results
Read

May 7, 2014 - Puma Biotechnology to Present at Bank of America Merrill Lynch 2014 Health Care Conference
Read

Apr. 7, 2014 - Puma Biotechnology Announces Presentation of Positive PB272 Phase II Data from I-SPY 2 TRIAL
Read

Mar. 12, 2014 - Puma Biotechnology to Present at Bank of America Merrill Lynch Smid Cap Conference
Read

Mar. 5, 2014 - Puma Biotechnology Announces Oral Presentation on I-SPY2 TRIAL at AACR Annual Meeting 2014
Read

Mar. 3, 2014 - Puma Biotechnology Reports Fourth Quarter and Full Year 2013 Financial Results
Read

Feb. 25, 2014 - Puma Biotechnology to Present at Cowen Health Care Conference
Read

Feb. 14, 2014 - Puma Biotechnology Closes $138 Million Public Offering of Common Stock
Read

Feb. 12, 2014 - Puma Biotechnology Announces Underwriters' Full Exercise of Option to Purchase Additional Shares
Read

Feb. 11, 2014 - Puma Biotechnology Prices Public Offering of Common Stock
Read

Feb. 6, 2014 - Puma Biotechnology Announces Positive Outcome of European Opposition Proceedings
Read


Corporate Fact Sheet

Puma Biotechnology, Inc.

10880 Wilshire Blvd., Suite 2150
Los Angeles, CA 90024
424-248-6500 Main
424-248-6501 Fax